Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Sanofi’s Dupilumab, Chugai’s PD-L1, Keytruda’s Lymphoma Use and More Clear MHLW Panel
November 7, 2017
- 3 Chuikyo Subcommittees to Hold Close-Door Debate on Pilot CEA Products Nov. 8
November 7, 2017
- LDP Group Starts Discussions on Drug Pricing Reform, Hears Opinions from JPMA Chief
November 6, 2017
- PMDA’s Review Division Remains in the Red, with Loss of 2-2.5 Billion Yen Expected for Full Year
November 6, 2017
- PMDA Aims to Speed Up Decision-Making, Streamline Operations
November 6, 2017
- MHLW Wants Chuikyo to Consider Measures to Promote Generic-Name Prescribing
November 6, 2017
- MHLW Advisory Panel Backs Nexium’s Pediatric Dosages, Oral Suspension Form
November 6, 2017
- Hefty Hirudoid Prescriptions Now under Scrutiny, Chuikyo Members at Odds over Restrictions
November 6, 2017
- Heads of Medicines Regulatory Agencies Agree to Promote Global Harmonization to Enable Use of Real World Data as Evidence
November 2, 2017
- Payer Rep Calls on Govt to Promote Use of Formularies at Hospitals to Ensure Use of Cheaper Option: Chuikyo
November 2, 2017
- Clinical Research Review System Based on Clinical Research Law to Start at Minimum of 11 Locations: MHLW
November 2, 2017
- PM Abe Watchful of Reward for Me-Too Drugs, CEFP Minutes Reveal
November 1, 2017
- Chuikyo Moots Possible Expansion of “Essential Drugs”; MHLW Pitches Antibacterial Eye Drops
October 30, 2017
- Kamoya Leaves Chuikyo as Industry Rep, Lauds Breakthrough for Essential Drug Rule
October 30, 2017
- Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too
October 30, 2017
- CEFP Kicks Off FY2018 Budget Debate with Major Focus on Scope of Off-Year Price Survey, Revision
October 27, 2017
- MHLW Issues Notification Revising GPSP Ordinance in Response to Medical Information Database
October 27, 2017
- Scrap Price Maintenance Premium, or Limit Scope of Products: MOF
October 26, 2017
- Chuikyo Proposes 5% ICER Deduction for Each Ethical/Societal Criteria Met
October 26, 2017
- Chuikyo OKs “5 Million Yen,” “10 Million Yen” Thresholds for 3-Segment CEA Price Adjustment Model
October 26, 2017
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…